EB-002

EB-002
Clinical data
Other namesEB002; EB-373; EB373; Synthetic psilocin prodrug
Routes of
administration		Oral
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken by mouth. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. Its exact chemical structure does not yet appear to have been disclosed.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.